文献速递膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤前列腺癌

血尿患者谁需检查?3556例前瞻性观察研究结果

Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients.
PubMed 文献 · Eur Urol · 2018-04-10

该研究在40家医院前瞻性观察3556例因血尿转诊检查的患者,尿路癌总发生率为10.0%,可见血尿患者癌检出率(13.8%)高于非可见血尿(3.1%)。高龄、男性和吸烟史与尿路癌诊断独立相关,非可见血尿中诊断的膀胱癌59.4%为高危、31.3%为肌层浸润。结果提示可见血尿应无论年龄均检查,非可见血尿虽风险低但低于指南转诊年龄阈值仍可检出有临床意义的癌。

要点

  • 可见血尿患者尿路癌检出率13.8%,应无论年龄均行检查。
  • 非可见血尿患者尿路癌检出率3.1%,但低于60岁仍可检出有临床意义的癌。
  • 高龄、男性、吸烟史与尿路癌诊断独立相关。

核心结论

  • 可见血尿患者无论年龄均应检查,非可见血尿患者以≥60岁为转诊年龄阈值可能遗漏有临床意义的尿路癌。

研究设计与样本

  • 2016年3月至2017年6月在40家医院开展的前瞻性观察研究(DETECT 1,NCT02676180),纳入3556例因血尿转诊检查的患者。

主要发现

  • 尿路癌总发生率为10.0%,其中膀胱癌8.0%、肾实质癌1.0%、上尿路移行细胞癌0.7%、前列腺癌0.3%。
  • 可见血尿患者尿路癌诊断率为13.8%,高于非可见血尿患者的3.1%。
  • 非可见血尿后诊断的膀胱癌中59.4%为高危癌,31.3%为肌层浸润。
  • 可见血尿<45岁患者癌发生率为3.5%(n=7),非可见血尿<60岁患者为1.0%(n=4)。
  • 高龄、男性和吸烟史与尿路癌诊断独立相关。

临床怎么用

  • 可见血尿患者应无论年龄均行进一步检查。
  • 对非可见血尿患者,仅以≥60岁作为转诊检查阈值可能遗漏部分尿路癌,需结合患者意愿与证据制定共识。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: There remains a lack of consensus among guideline relating to which patients require investigation for haematuria. We determined the incidence of urinary tract cancer in a prospective observational study of 3556 patients referred for investigation of haematuria across 40 hospitals between March 2016 and June 2017 (DETECT 1; ClinicalTrials.gov: NCT02676180) and the appropriateness of age at presentation in cases with visible (VH) and nonvisible (NVH) haematuria. The overall incidence of urinary tract cancer was 10.0% (bladder cancer 8.0%, renal parenchymal cancer 1.0%, upper tract transitional cell carcinoma 0.7%, and prostate cancer 0.3%). Patients with VH were more likely to have a diagnosis of urinary tract cancer compared with NVH patients (13.8% vs 3.1%). Older patients, male gender, and smoking history were independently associated with urinary tract cancer diagnosis. Of bladder cancers diagnosed following NVH, 59.4% were high-risk cancers, with 31.3% being muscle invasive. The incidence of cancer in VH patients <45 yr of age was 3.5% (n=7) and 1.0% (n=4) in NVH patients <60 yr old. Our results suggest that patients with VH should be investigated regardless of age. Although the risk of urinary tract cancer in NVH patients is low, clinically significant cancers are detected below the age threshold for referral for investigation. PATIENT SUMMARY: This study highlights the requirement to investigate all patients with visible blood in the urine and an age threshold of ≥60 yr, as recommended in some guidelines, as the investigation of nonvisible blood in the urine will miss a significant number of urinary tract cancers. Patient preference is important, and evidence that patients are willing to submit to investigation should be considered in reaching a consensus recommendation for the investigation of haematuria. International consensus to guide that patients will benefit from investigation should be developed.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Tan WS, Feber A, Sarpong R, et al. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. Eur Urol. 2018. PMID: 29653885. doi:10.1016/j.eururo.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。